Literature DB >> 7912534

Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.

R J Parker1, M D Dabholkar, K B Lee, F Bostick-Bruton, E Reed.   

Abstract

Taxol and cisplatin are the two most effective agents discovered to date for treating advanced-stage cancer of the ovary. Learning how best to combine these agents is the focus of preclinical and clinical studies conducted at a number of institutions. Taxol's effect on cellular sensitivity to cisplatin was studied in paired cisplatin-sensitive A2780 and cisplatin-resistant A2780/CP70 human ovarian cancer cell lines. Cisplatin growth curves were generated under conditions of specific sequencing with Taxol, and IC50s (concentrations at which growth is inhibited to 50% of control) for cisplatin were obtained and compared. Taxol was used at an IC10 dose in all experiments. Taxol treatments were for 24 hours and cisplatin treatments were for 1 hour in all experiments. Dimethyl sulfoxide (DMSO) was the diluent for all Taxol stock solutions. Separately, the effects of Taxol and DMSO on cisplatin cellular accumulation were measured. End points reported include measures of cytotoxicity and Taxol effects on cisplatin cellular accumulation. Using a microculture tetrazolium assay, cisplatin growth curves were obtained under the influence of Taxol, at a Taxol dose of 3 nM for both cell lines. DMSO alone had no effect on tumor cell growth. In A2780 cells, the influence of Taxol on cisplatin cytotoxicity was modest, whereas cisplatin-induced cell kill was augmented 1.5-fold when cisplatin was given immediately after Taxol. In A2780/CP70 cells, Taxol augmented cisplatin-induced cell kill by 30-fold when cisplatin was given immediately after Taxol; 75-fold when cisplatin was given 24 hours after completion of Taxol; and 19-fold when cisplatin was given 48 hours after completion of Taxol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7912534

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  10 in total

Review 1.  Chemotherapy in non-small cell lung cancer.

Authors:  C J Sweeney; A B Sandler
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

2.  Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

Authors:  E K Rowinsky; W A Flood; S E Sartorius; K M Bowling; D S Ettinger
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 3.  A preliminary risk-benefit assessment of paclitaxel.

Authors:  R J Bitton; W D Figg; E Reed
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

4.  Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Authors:  Gisele A Sarosy; Mahrukh M Hussain; Michael V Seiden; Arlan F Fuller; Najmosama Nikrui; Annekathryn Goodman; Lori Minasian; Eddie Reed; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

5.  Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.

Authors:  Li Wang; Yunxin Zhang; Jinxia Zhao; Erlong Xiao; Jianzhong Lu; Shengjun Fu; Zhiping Wang
Journal:  Tumour Biol       Date:  2014-08-02

6.  Nucleotide excision repair and anti-cancer chemotherapy.

Authors:  E Reed
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

7.  Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.

Authors:  C Kosmas; G Vorgias; G Tsakonas; P Politis; T Daladimos; E Panagiotidi; T Papachrysanthou; D Moschovis; N Kalinoglou; N Tsavaris; A Karabelis; N Mylonakis
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

8.  Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.

Authors:  C Kosmas; N B Tsavaris; A Polyzos; N A Malamos; M Katsikas; M J Antonopoulos
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.

Authors:  M Koczywas; P H Frankel; T W Synold; H-J Lenz; J E Mortimer; A B El-Khoueiry; D R Gandara; M C Cristea; V M Chung; D Lim; K L Reckamp; D H Lau; L A Doyle; C Ruel; M I Carroll; E M Newman
Journal:  Br J Cancer       Date:  2014-10-28       Impact factor: 7.640

10.  Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.

Authors:  C Kosmas; N Mylonakis; G Tsakonas; G Vorgias; N Karvounis; N Tsavaris; T Daladimos; N Kalinoglou; N Malamos; T Akrivos; A Karabelis
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.